Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

Tolaney SM, Sammons S, Sandoval-Leon A, Cortes J, Liepa AM, Grimes BR, He D, Cui ZL, Roose J, Gathirua-Mwangi W, Moreira K, O'Shaughnessy J, Neven P, Johnston SRD, Rugo HS.

Open source

DOI
10.1016/j.esmoop.2025.106021
Published
2026-01-19
Container
ESMO Open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2025.106021,
  title = {Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.},
  author = {Tolaney SM and  Sammons S and  Sandoval-Leon A and  Cortes J and  Liepa AM and  Grimes BR and  He D and  Cui ZL and  Roose J and  Gathirua-Mwangi W and  Moreira K and  O'Shaughnessy J and  Neven P and  Johnston SRD and  Rugo HS.},
  year = {2026},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2025.106021},
  url = {https://doi.org/10.1016/j.esmoop.2025.106021}
}

RIS

TY  - JOUR
TI  - Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.
AU  - Tolaney SM
AU  -  Sammons S
AU  -  Sandoval-Leon A
AU  -  Cortes J
AU  -  Liepa AM
AU  -  Grimes BR
AU  -  He D
AU  -  Cui ZL
AU  -  Roose J
AU  -  Gathirua-Mwangi W
AU  -  Moreira K
AU  -  O'Shaughnessy J
AU  -  Neven P
AU  -  Johnston SRD
AU  -  Rugo HS.
PY  - 2026
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2025.106021
UR  - https://doi.org/10.1016/j.esmoop.2025.106021
ER  - 

APA

SM, T., S, S., A, S., J, C., AM, L., BR, G., D, H., ZL, C., J, R., W, G., K, M., J, O., P, N., SRD, J., & HS., R. (2026). Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.. ESMO Open. https://doi.org/10.1016/j.esmoop.2025.106021

Source records